Table 2.

Clinical outcomes of three patients with advanced solid tumors who received matched therapy based on ctDNA analysis.

Pt. ID	ctDNA biomarker	Matched therapy	Best RECIST response	PFS*, months	Progr.status	Subsequent Rx	Survival status	OS†, months
001	BRCA2 R3052W	PARP inhibitor	PR	22.6+	N/A	N/A	Alive	22.6+
002	RAF1 amplification	MEK/RAF pathway inhibitor	SD	20.2	PD	Investigational	Alive	28.4+
003	BRCA1 Q356*	PARP inhibitor	SD	9.1	PD	Doxorubicin; radiotherapy	Alive	14.8+

N/A, non-applicable; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; Progr., progression; Rx, therapy; SD, stable disease.

BRAC1, breast cancer type 1; BRAC2, breast cancer type 2; MEK, mitogen-activated protein kinase kinase; PARP, poly (ADP-ribose) polymerase; RAF1, rapidly accelerated fibrosarcoma 1.

^*Progression-free survival is measured in months from cycle 1, day 1 to time of radiologic scan showing progressive disease.

^†Overall survival is measured in months from cycle 1, day 1 to the most recent time of this report.